CEO to take break from running Germany's Uniper for cancer treatment
Klaus Schaefer, CEO of German energy utility company Uniper SE attends a news conference in Duesseldorf, Germany, March 8, 2018. REUTERS/Thilo Schmuelgen
BERLIN (Reuters) - The chief executive of Germany's Uniper
"Klaus Schaefer has informed the Chairman of the Supervisory Board, Dr. Bernhard Reutersberg, that he is suffering from cancer and that the treatment will take several months," Uniper said in a statement on Wednesday.
Uniper's supervisory and management boards will now arrange how to divide up Schaefer's duties during his absence, the company said in a short statement.
Schaefer, 51, has been CEO since Jan 1, 2016, when the company began operating as a separate unit of E.ON
He has vowed to defend the energy group's independence, after Finnish rival Fortum
His opposition to the deal had prompted activist investor Elliott to try to launch a probe into whether managers had actively worked to obstruct the sale. A vote on the motion was delayed in June, leaving the fate of Uniper management in Fortum's hands.
Fortum said last month that it was seeking to reset its relationship with Uniper.
Carmaker Fiat Chrysler
After a Swiss hospital said it had been treating Marchionne for more than a year, questions were raised about how much the company knew before it made the situation public.
Fiat Chrysler said that, due to medical privacy, it had no knowledge of the facts relating to Marchionne's health.
(Reporting by Victoria Bryan; Editing by Caroline Copley and Adrian Croft)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Good chance that trapped workers are still alive in Nepal hydropower plant, official says
- German cabinet approves €10 billion income-tax reform
- Two injured in blast at train station in southern Germany
Create E-mail Alert Related Categories
ReutersRelated Entities
Chrysler LLCSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share